Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Cabozantinib as an emerging treatment for sarcoma — Patrick Schöffski (2020) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Cabozantinib as an emerging treatment for sarcoma
Shared by
Jean Yves Blay
Cabozantinib as an emerging treatment for sarcoma
Article
2020
en
Authors
PS
Patrick Schöffski
Jean Yves Blay
IR
Isabelle Ray‐Coquard
Abstract
1 min read
Cabozantinib has shown promising activity for the treatment of various sarcomas, supporting further evaluation in this setting.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2021
Cabozantinib: An evolving therapy for hepatocellular carcinoma
Anthony B. El-Khoueiry
,
Diana L. Hanna
,
Josep M. Llovet
,
Robin Kate Kelley
Cancer Treatment Reviews
Letter
2019
Cabozantinib for advanced hepatocellular carcinoma
Masatoshi Kudo
Dataset
Supplementary Material for: Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety
Philippe Merle
,
Masatoshi Kudo
,
Stanimira Krotneva
,
Kirhan Özgürdal
,
Su Y.
,
Irina Proskorovsky
Article
2022
Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety
Philippe Merle
,
Masatoshi Kudo
,
Stanimira Krotneva
,
Kirhan Özgürdal
,
Yun Su
,
Irina Proskorovsky
Article
2022
Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 ‘CaboGIST’
Anastasios Kyriazoglou
,
Pieter Jespers
,
Vincent Vandecavaye
,
Olivier Mir
,
Bernd Kasper
,
Zsuzsanna Pápai
,
Jean Yves Blay
,
Antoîne Italiano
,
Facundo Zaffaroni
,
Saskia Litière
,
Axelle Nzokirantevye
,
Patrick Schöffski
Discussion(0)
No comments yet. Be the first to comment.